Doxorubicin-associated mitochondrial iron accumulation promotes cardiotoxicity

Doxorubicin is a widely used as a component of chemotherapy regimes; however, the use of doxorubicin is associated with severe cardiotoxicity. It is unclear exactly how doxorubicin promotes cardiotoxicity, but it has been proposed that doxorubicin-associated cardiomyopathy develops as the result of reactive oxygen species (ROS) production and iron accumulation.

In this issue of the Journal of Clinical Investigation, Hossein Ardehali and colleagues at Northwestern University determined that doxorubicin accumulates within the mitochondria of cardiomyocytes and this accumulation promotes mitochondrial ROS production and iron accumulation.

In a mouse model of doxorubicin-associated cardiotoxicity, overexpression of a protein that enhances mitochondrial iron transport reduced mitochondrial iron, ROS, and protected animals from doxorubicin-induced cardiomyopathy. Treatment of animals with dexrazoxane, which attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Furthermore, heart samples from patients undergoing doxorubicin therapy revealed higher levels of mitochondrial iron in patients with cardiomyopathies compared to patients without .

These data suggest that therapies that limit mitochondrial iron accumulation have potential to limit -associated cardiotoxicity.

More information: J Clin Invest. DOI: 10.1172/JCI72931

add to favorites email to friend print save as pdf

Related Stories

A search for protection against chemotherapy cardiotoxicity

Dec 20, 2007

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing ...

Polymer nanoparticle overcomes anticancer drug resistance

Aug 17, 2012

In a nanotechnology two-for-one, researchers at the Johns Hopkins University Center of Cancer Nanotechnology Excellence (Hopkins CCNE) have created a polymer nanoparticle that overcomes tumor resistance to the common anticancer ...

Overcoming cancer drug resistance with nanoparticles

Jan 20, 2012

One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

3 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

Vaccines may make war on cancer personal

3 hours ago

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...

Funding to investigate an alternative to chemotherapy

4 hours ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.